证券代码：688222 证券简称：成都先导 公告编号：2024-037 成都先导药物开发股份有限公司 关于股东钧天创业投资有限公司、重庆渤溢新天 股权投资基金合伙企业（有限合伙） 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东的持股基本情况 截至本公告披露日，公司股东钧天创投持有公司股份 1,831,448 股，占公司 总股本的 0.46%；钧天创投与公司股东深圳市钧天创业投资有限公司（以下简称 "钧天投资"）均由深圳市九野钧天创业投资管理有限公司担任基金管理人，二者 构成一致行动关系，钧天投资持有公司股份 14,102,516 股，占公司总股本的 3.52%。 钧天投资、钧天创投合计持有公司股份 15,933,964 股，占公司总股本的 3.98%。 1 本次减持计划的股东钧天创业投资有限公司（以下简称"钧天创投"）、 重庆渤溢新天股权投资基金合伙企业（有限合伙）（以下简称"渤溢新 天"）有关于减持意向的承诺： （1） 减持方式：减持成都先导药物开发股份有限公司 ...

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][67][68] Core Views - The company has successfully established four core platforms: DEL, FBDD/SBDD, STO, and TPD, focusing on small molecules and nucleic acid drugs, which enhances its competitiveness in the CRO field [3][67] - The company is expected to gradually recover its performance, with projected revenues of 4.47 billion, 5.56 billion, and 7.10 billion yuan for 2024, 2025, and 2026, respectively, representing year-on-year growth rates of 20.3%, 24.5%, and 27.6% [3][67] - The reasonable price range for the company's stock is estimated to be between 13.48 and 14.85 yuan, indicating a potential upside of 3% to 14% from the current price [3][68] Summary by Sections Financial Performance - In the first three quarters of 2024, the company achieved a revenue of 298 million yuan, a year-on-year increase of 21.4%, and a net profit attributable to shareholders of 30 million yuan, up 64.7% [1][6] - The company’s revenue for the full year of 2023 was 371 million yuan, reflecting a growth of 12.6% compared to the previous year [1][4] Revenue Breakdown - The revenue from the DEL platform was 122 million yuan, an increase of 2.93%, while the FBDD/SBDD platform generated 93 million yuan, up 58.21% [8][11] - The STO platform achieved a revenue of 38 million yuan, growing by 39.81%, and the TPD platform brought in 15 million yuan, an increase of 47.92% [8][11] Profitability Metrics - The gross margin for the first three quarters of 2024 was 49.3%, an increase of 5.63 percentage points, and the net profit margin was 10.1%, up 2.66 percentage points [13][14] - The company’s net profit attributable to shareholders is projected to reach 50 million, 63 million, and 83 million yuan for 2024, 2025, and 2026, respectively, with growth rates of 21.6%, 27.3%, and 31.5% [3][67] Market Position and Competitive Advantage - The company possesses over 1.2 trillion compounds in its drug seed library, making it a leader in the new drug development CRO industry [2][15] - The integration of AI and automation with existing platforms is expected to enhance drug discovery capabilities and optimize processes [45][46] Future Outlook - The company is expected to continue expanding its core platforms and enhancing its technological capabilities, which will support its growth trajectory in the coming years [3][67] - The strategic partnerships and collaborations with international pharmaceutical companies further solidify the company's position in the market [31][41]

证券代码：688222 证券简称：成都先导 公告编号：2024-036 成都先导药物开发股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 11 月 5 日(星期二)至 11 月 11 日(星期一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过投资者 关系邮箱（investors@hitgen.com）进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2024 年 10 月 26 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 11 月 12 日(星期二) 14:00-15:00 举行 2024 年第三季度业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召 ...

成都先导（688222.SH） 医疗服务 证券研究报告/公司点评报告 2024 年 10 月 28 日 Q3 呈逐步恢复态势，看好 DEL 平台长期发展 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥103,549,898.82, representing a year-over-year increase of 14.96%[2] - The net profit attributable to shareholders for Q3 2024 was ¥19,922,553.96, reflecting a significant increase of 59.82% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥15,252,346.18, with a year-over-year increase of 39,114.40%[2] - The basic earnings per share for Q3 2024 was ¥0.05, up 66.67% from the previous year[3] - Total operating revenue for the first three quarters of 2024 reached RMB 298,269,775.63, an increase of 21.3% compared to RMB 245,729,314.33 in the same period of 2023[13] - Net profit for the first three quarters of 2024 was RMB 28,665,735.55, compared to RMB 18,438,333.95 in 2023, representing a growth of 55.5%[15] - The company's operating profit for the first three quarters of 2024 was RMB 26,015,358.54, significantly higher than RMB 7,321,397.06 in the same period last year[15] - The total comprehensive income for the first three quarters of 2024 was RMB 35,378,804.00, compared to RMB 28,129,435.41 in 2023, indicating an increase of 25.9%[16] - Basic earnings per share for the first three quarters of 2024 were RMB 0.08, up from RMB 0.05 in the same period of 2023[16] Research and Development - The total R&D investment for Q3 2024 was ¥20,917,934.89, a decrease of 11.34% compared to the same period last year[3] - The company’s R&D investment accounted for 20.20% of operating revenue in Q3 2024, a decrease of 0.82 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2024 amounted to RMB 51,651,962.63, a decrease from RMB 58,256,296.89 in 2023, showing a reduction of 11.0%[15] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,722,496,578.95, showing a slight decrease of 0.41% from the end of the previous year[3] - The company's total assets as of September 30, 2024, amount to approximately 1.72 billion RMB, a slight decrease from 1.73 billion RMB at the end of 2023[12] - The total current liabilities decreased to approximately 69.28 million RMB from 85.98 million RMB[12] - The company's total liabilities decreased from RMB 346,566,991.96 to RMB 320,757,631.35, a reduction of 7.4%[13] - The total equity attributable to shareholders of the parent company increased from RMB 1,358,124,788.21 to RMB 1,378,326,364.55, reflecting a growth of 1.5%[13] - Deferred income tax liabilities decreased from RMB 17,697,120.28 to RMB 15,905,006.57, a decline of 10.1%[13] Cash Flow - The company reported a net cash flow from operating activities of ¥98,963,885.55 for the year-to-date, an increase of 50.41% compared to the same period last year[2] - In the first three quarters of 2024, the cash inflow from operating activities totaled CNY 341,507,776.40, compared to CNY 310,006,995.10 in the same period of 2023, representing an increase of approximately 10.5%[18] - The net cash flow from investment activities was CNY -687,586.08, a significant improvement from CNY -104,127,887.32 in the previous year, indicating a reduction in cash outflow[18] - The company received CNY 1,590,000,000.00 from investment recoveries, up from CNY 1,254,000,000.00 in the same period last year, marking an increase of approximately 26.7%[18] - The total cash outflow from investment activities was CNY 1,603,054,130.49, compared to CNY 1,369,169,439.17 in the previous year, reflecting an increase of about 17%[18] - The net cash flow from financing activities was CNY -39,033,990.56, worsening from CNY -17,238,002.39 in the same period last year, indicating increased cash outflow[19] - The cash and cash equivalents at the end of the period amounted to CNY 428,952,786.46, up from CNY 305,245,536.37 at the end of the same period last year, representing an increase of approximately 40.5%[19] - The company reported a cash inflow from tax refunds of CNY 14,280,949.99, compared to CNY 8,255,231.44 in the previous year, showing an increase of about 73.5%[18] - The total cash outflow for employee compensation was CNY 128,463,643.88, slightly down from CNY 133,437,780.49 in the previous year, indicating a decrease of about 3.2%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,663, with the top ten shareholders holding significant stakes[8] - JIN LI (李进) holds 81,876,948 shares, representing 20.43% of the total shares[9] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[9] - There are no significant related party transactions or concerted actions among the top shareholders[9] Other Information - The company received government subsidies amounting to ¥1,723,912.99 in Q3 2024, which is lower than the previous year's amount[4] - The inventory level as of September 30, 2024, is 29.93 million RMB, compared to 28.18 million RMB in the previous year[11] - The company reported a significant increase in long-term equity investments, rising to 14.62 million RMB from 12.38 million RMB[11] - The company has not identified any other important information regarding its operational performance during the reporting period[10] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting practices[20] - The company experienced a foreign exchange loss of CNY -2,880,259.64, contrasting with a gain of CNY 4,452,847.37 in the same period last year, highlighting a significant change in currency impact[19]

证券代码：688222 证券简称：成都先导 公告编号：2024-035 成都先导药物开发股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事 9 人，出席 9 人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 09 月 13 日 （二） 股东大会召开的地点：成都市双流区慧谷东一路 8 号 C2 栋成都先导药物 开发股份有限公司二楼大会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的表决权数量 | 169,426,141 | | 普通股股东所持有表决权数量 | 169,426,141 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 4 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 2024 年第三次临时股东大会的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东大会规则（2022 年修订）》（以下 简称《股东大会规则》）等中国现行有效的有关法律、行政法规、部门规章、 规范性文件（以下合称"法律法规"，仅为本法律意见书法律适用之目的，不包括 中国香港特别行政区、中国澳门特别行政区及台湾地区的法律法规）及《成都 先导药物开发股份有限公司章程》（以下简称《公司章程》）的有关规定，就 贵公司 2024 年第三次临时股东大会（以下简称"本次股东大会"）有关事宜出 具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序是否符合法律、行政法 规、《股东大会规则》和《 ...

证券代码：688222 证券简称：成都先导 公告编号：2024-034 成都先导药物开发股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得政府补助的基本情况 成都先导药物开发股份有限公司（以下简称"公司"）英国全资子公司 Vernalis (R&D) Limited 于近日收到政府补助款项 1,049,906.09 英镑（折合人民币 9,492,305.95 元），均为与收益相关的政府补助。 成都先导药物开发股份有限公司董事会 2024 年 9 月 13 日 1 根据《企业会计准则第 16 号——政府补助》有关规定，公司获得的上述政 府补助款项，预计对公司 2024 年度经营活动产生的现金流量净额产生一定的积 极影响（该金额包含于 2023 年财务报表的其他应收款及其他流动资产科目中， 且已于 2023 年年度利润表中体现）。 上述政府补助未经审计，具体的会计处理以及对公司 2024 年度损益的最终 影响以审计机构年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 ...

证券代码：688222 证券简称：成都先导 公告编号：2024-033 成都先导药物开发股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 9 月 11 日(星期三) 至 9 月 19 日(星期四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过投资者 关系邮箱（investors@hitgen.com）进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2024 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半 年度经营成果、财务状况，公司计划于 2024 年 9 月 20 日(星期五)下 午 13:00-14:00 举行 2024 年半年度业绩说明会，就投资者关心的问题 进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开， ...

整体业务稳步恢复，新业务平台不断开拓有望带来长期增长 成都先导（688222.SH）/医药生物 证券研究报告/公司点评 2024 年 09 月 04 日 [Table_Industry] [Table_Title] 评级：买入(维持) 市场价格：8.79 分析师：祝嘉琦 执业证书编号：S0740519040001 电话：021-20315150 Email：zhujq@zts.com.cn 分析师：崔少煜 执业证书编号：S0740522060001 Email：cuisy@zts.com.cn | --- | --- | --- | --- | --- | --- | |---------------------------------------------|--------------|--------|--------|--------|--------| | [Table_Finance] 公司盈利预测及估值 \n指标 | \n2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入（百万元） | 329.65 | 371.32 | 434.94 | 518.31 ...